Veracyte, Inc. Announces CEO Succession Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- KBR names its Mission Technology Solutions spinoff Trinzic
- Wall Street ends sharply higher, lifted by soaring Microsoft
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Veracyte, Inc (VCYT) PT Lowered to $54 at Needham & Company
May 11, 2021 6:34 AM EDTNeedham & Company analyst Stephen Unger lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $54.00 (from $88.00) while maintaining a Buy rating.
The analyst commented, "VCYT's 1Q21 revenue was in line with its 4/16/21 preannouncement and EPS adjusted for one-time acquisition expenses beat consensus. Organic... More
